TZF Polfa and Ecopia – Cooperation to Enhance Access to Medicines in Ethiopia

TZF Polfa S.A. has signed a Letter of Intent (LOI) with Ecopia, initiating cooperation aimed at developing the pharmaceutical market in Ethiopia and improving access to critically important medicines.

The agreement marks the first step toward building a long-term partnership, combining TZF Polfa’s expertise in development, manufacturing, and regulatory compliance with Ecopia’s experience in the local market, distribution, and identification of regional healthcare needs.

The priority of the cooperation is to ensure access to key therapeutic areas, in particular:

• antibiotics (Priority 1), including penicillins, cephalosporins, and combination therapies used in the treatment of severe infections and sepsis,
• medicines used in the treatment of infectious diseases,
• hospital medicines (injectables), including therapies used in emergency care and intensive care units,
• medicines for chronic diseases, including diabetes care,
• anti-inflammatory and pain relief medicines,
• selected specialty products, including oncology therapies at a later stage of cooperation.

In the first phase, the parties will focus on the rapid launch of distribution activities and leveraging existing capabilities to achieve short-term market impact.

In parallel, a long-term cooperation framework will be developed, including:

• a Distribution Agreement,
• a strategic Memorandum of Understanding (MoU),
• development of initiatives in local manufacturing, research, and development,
• dialogue with public administration and governmental institutions.

The cooperation aligns with the global trend of building resilient pharmaceutical supply chains and improving access to therapies in regions with growing healthcare needs.